Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 and Glecirasib in KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
NCT07827261Phase 2Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07827261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827261.